静注用イブプロフェンの世界市場レポート 2025年

静注用イブプロフェン市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は12.1%で、148億6,000万米ドルに成長します。予測期間中の成長は、ヘルスケア投資の増加、小児患者人口の増加、疼痛や発熱の有病率の増加、高齢化、先進的な医薬品治療の採用増加など、いくつかの要因に起因しています。この期間の主な動向としては、高度な治療ソリューションの開発、単回投与製剤の出現、個別化医療の進展、多剤併用による疼痛管理プロトコールへの統合、併用療法の進展などが挙げられます。

疼痛障害の有病率の増加は、今後数年間におけるイブプロフェン静注市場の成長を促進すると予想されます。疼痛障害とは、日常生活に支障をきたす持続的または慢性的な痛みを特徴とする病状であり、多くの場合、神経、筋骨格系、炎症性の問題が原因です。高齢者は関節炎、変形性関節症、神経痛などの慢性疾患を発症する可能性が高く、効果的な鎮痛剤に対する需要が高まるためです。イブプロフェンの静脈内投与は、疼痛を迅速に緩和することで疼痛管理を助け、特に急性痛や術後痛に適しています。炎症を抑え、患者の快適性を高めることで、医療現場での治療効果を総合的に向上させる。例えば、2024年1月、英国のOffice for Health Improvement and Disparitiesは、長期的な筋骨格系疾患を有すると自己申告した16歳以上の人の割合が、2022年の17.6％から2023年には18.4％に増加したと報告しました。その結果、疼痛障害の有病率の上昇がイブプロフェン静注市場の成長に寄与しています。

イブプロフェン静注市場の各社は、オピオイド依存のリスクを低減しながら疼痛管理を改善するため、オピオイドフリーの鎮痛薬など、先進的な製剤の開発に注力しています。オピオイドを含まない鎮痛薬とは、オピオイドを含まない鎮痛薬のことで、これにより中毒やオピオイド関連の副作用のリスクを排除することができます。例えば、2024年2月、英国の製薬会社Hikma Pharmaceuticals plcは、2023年10月のFDA承認に続き、米国でCOMBOGESIC IV（アセトアミノフェン、イブプロフェン）注射剤を発売しました。オピオイドを含まないこの静注用鎮痛薬は、軽度から中等度の疼痛の緩和、および中等度から重度の疼痛管理の補助を目的としています。作用機序の異なる2つの有効成分を配合することで、COMBOGESIC IVは医療従事者に新規の非オピオイド鎮痛ソリューションを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の静注用イブプロフェンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の静注用イブプロフェン市場：成長率分析
• 世界の静注用イブプロフェン市場の実績：規模と成長、2019年～2024年
• 世界の静注用イブプロフェン市場の予測：規模と成長、2024年～2029年、2034年
• 世界の静注用イブプロフェン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の静注用イブプロフェン市場：製品タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 従来の静注用イブプロフェン
• 高濃度静注用イブプロフェン
• 世界の静注用イブプロフェン市場：含有量別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 100ミリグラム（mg）
• 200ミリグラム（mg）
• 400ミリグラム（mg）
• 800ミリグラム（mg）
• 世界の静注用イブプロフェン市場：年齢層別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 小児科
• 大人
• 世界の静注用イブプロフェン市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 痛み
• 熱
• 炎症
• その他の用途
• 世界の静注用イブプロフェン市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• 外来手術センター
• クリニック
• その他のエンドユーザー
• 世界の静注用イブプロフェン市場、従来の静脈内（IV）イブプロフェンの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 小児科用静注用イブプロフェン
• 成人用静注用イブプロフェン
• 世界の静注用イブプロフェン市場、高濃度静脈内（IV）イブプロフェンの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 単回投与バイアル
• マルチドーズバイアル

第7章 地域別・国別分析

• 世界の静注用イブプロフェン市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の静注用イブプロフェン市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 静注用イブプロフェン市場：競合情勢
• 静注用イブプロフェン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Fresenius SE & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Baxter International
• Mylan N.V.
• Sandoz Group AG
• Grifols S.A.
• Dr. Reddy's Laboratories
• Hikma Pharmaceuticals plc
• CSL Limited
• Eurolife Healthcare Pvt. Ltd.
• B. Braun Holding GmbH & Co. KG
• AFT Pharmaceuticals Ltd
• Cumberland Pharmaceuticals Inc.
• Delex Pharma International Inc.
• Recordati Rare Diseases Inc.
• Xgen Pharmaceuticals Djb Inc.
• Wellona Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 静注用イブプロフェン市場2029年：新たな機会を提供する国
• 静注用イブプロフェン市場2029年：新たな機会を提供するセグメント
• 静注用イブプロフェン市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Intravenous (IV) Ibuprofen is a medication administered directly into the bloodstream through an intravenous route, primarily used for providing rapid pain relief and reducing inflammation or fever, especially in patients who are unable to take oral medications. It works by inhibiting the production of prostaglandins, which are responsible for causing pain and inflammation. IV ibuprofen is commonly used in clinical settings, particularly for postoperative pain and other acute conditions that require quick relief.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main product types in the intravenous (IV) ibuprofen market include conventional intravenous (IV) ibuprofen and high-concentration intravenous (IV) ibuprofen. Conventional intravenous (IV) ibuprofen is the standard formulation used to administer ibuprofen directly into the bloodstream for pain relief, inflammation reduction, and fever management, typically in hospital settings for acute or postoperative pain. The available strengths for intravenous ibuprofen include 100 mg, 200 mg, 400 mg, and 800 mg. IV ibuprofen is used for a range of conditions, including pain, fever, and inflammation, across different age groups, including pediatrics and adults. The key end-users include hospitals, ambulatory surgical centers, clinics, and other healthcare settings.

The intravenous (IV) ibuprofen market research report is one of a series of new reports from The Business Research Company that provides intravenous (IV) ibuprofen market statistics, including intravenous (IV) ibuprofen industry global market size, regional shares, competitors with a intravenous (IV) ibuprofen market share, detailed intravenous (IV) ibuprofen market segments, market trends and opportunities, and any further data you may need to thrive in the intravenous (IV) ibuprofen industry. This intravenous (IV) ibuprofen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The intravenous (IV) ibuprofen market size has grown rapidly in recent years. It will grow from$8.35 billion in 2024 to $9.4 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to several factors, including the increasing prevalence of chronic diseases, a rise in surgical procedures, and a growing emphasis on minimizing opioid usage.

The intravenous (IV) ibuprofen market size is expected to see rapid growth in the next few years. It will grow to$14.86 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth during the forecast period can be attributed to several factors, including higher healthcare investments, a growing pediatric patient population, an increase in the prevalence of pain and fever, an aging population, and a rise in the adoption of advanced pharmaceutical treatments. Key trends during this period include the development of advanced therapeutic solutions, the emergence of single-dose formulations, progress in personalized medicine, integration into multimodal pain management protocols, and advancements in combination therapies.

The growing prevalence of pain disorders is expected to drive the growth of the intravenous ibuprofen market in the coming years. Pain disorders are medical conditions characterized by persistent or chronic pain that impairs daily functioning, often due to nerve, musculoskeletal, or inflammatory issues. The increase in pain disorders is largely attributed to the aging population, as older adults are more likely to develop chronic conditions such as arthritis, osteoarthritis, and nerve pain, leading to a higher demand for effective pain relief. Intravenous ibuprofen aids pain management by providing rapid relief, making it particularly suitable for acute and postoperative pain. It works by reducing inflammation and enhancing patient comfort, improving the overall effectiveness of treatment in medical settings. For example, in January 2024, the Office for Health Improvement and Disparities in the UK reported that the percentage of individuals aged 16 and older who self-reported having a long-term musculoskeletal condition increased to 18.4% in 2023, up from 17.6% in 2022. As a result, the rising prevalence of pain disorders is contributing to the growth of the intravenous ibuprofen market.

Companies in the intravenous ibuprofen market are focusing on developing advanced drug formulations, such as opioid-free analgesics, to improve pain management while reducing the risk of opioid dependence. An opioid-free analgesic is a pain-relieving medication that does not contain opioids, thereby eliminating the risks of addiction and opioid-related side effects. For instance, in February 2024, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, introduced COMBOGESIC IV (acetaminophen and ibuprofen) injection in the U.S. following FDA approval in October 2023. This intravenous, opioid-free analgesic is intended for the relief of mild to moderate pain and as an adjunct for managing moderate to severe pain. By combining two active ingredients with distinct mechanisms of action, COMBOGESIC IV offers a novel non-opioid pain management solution for healthcare providers.

In May 2024, Halex Istar Industria Farmaceutica SA, a Brazil-based pharmaceutical company, entered into a partnership with AFT Pharmaceuticals Ltd. to expand the distribution of Maxigesic IV (paracetamol + ibuprofen IV) in Brazil. This collaboration aims to provide effective non-opioid pain management solutions to the Brazilian market. AFT Pharmaceuticals Ltd., based in New Zealand, specializes in intravenous pain relief products.

Major players in the intravenous (iv) ibuprofen market are Pfizer Inc., Sanofi S.A., Novartis AG, Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., Baxter International, Mylan N.V., Sandoz Group AG, Grifols S.A., Dr. Reddy's Laboratories, Hikma Pharmaceuticals plc, CSL Limited, Eurolife Healthcare Pvt. Ltd., B. Braun Holding GmbH & Co. KG, AFT Pharmaceuticals Ltd, Cumberland Pharmaceuticals Inc., Delex Pharma International Inc., Recordati Rare Diseases Inc., Xgen Pharmaceuticals Djb Inc., Wellona Pharma, and Hyloris Pharmaceuticals SA.

North America was the largest region in the intravenous (IV) ibuprofen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intravenous (IV) ibuprofen report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the intravenous (IV) ibuprofen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intravenous (IV) ibuprofen market consists of sales of pediatric intravenous (IV) ibuprofen, intravenous (IV) ibuprofen concentrate and pre-mixed intravenous (IV) ibuprofen bags. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Intravenous (IV) Ibuprofen Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on intravenous (iv) ibuprofen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for intravenous (iv) ibuprofen ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The intravenous (iv) ibuprofen market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Conventional Intravenous (IV) Ibuprofen; High-Concentration Intravenous (IV) Ibuprofen
• 2) By Strength: 100 Milligrams (mg); 200 Milligrams (mg); 400 Milligrams (mg); 800 Milligrams (mg)
• 3) By Age Group: Pediatrics; Adults
• 4) By Application: Pain; Fever; Inflammation; Other Applications
• 5) By End-User: Hospitals; Ambulatory Surgical Centers; Clinics; Other End-Users
• Subsegments:
• 1) By Conventional Intravenous (IV) Ibuprofen: Pediatric Intravenous (IV) Ibuprofen; Adult Intravenous (IV) Ibuprofen
• 2) By High-Concentration Intravenous (IV) Ibuprofen: Single-Dose Vial; Multi-Dose Vial
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Novartis AG; Fresenius SE & Co. KGaA; Teva Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Intravenous (IV) Ibuprofen Market Characteristics

3. Intravenous (IV) Ibuprofen Market Trends And Strategies

4. Intravenous (IV) Ibuprofen Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Intravenous (IV) Ibuprofen Growth Analysis And Strategic Analysis Framework

• 5.1. Global Intravenous (IV) Ibuprofen PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Intravenous (IV) Ibuprofen Market Growth Rate Analysis
• 5.4. Global Intravenous (IV) Ibuprofen Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Intravenous (IV) Ibuprofen Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Intravenous (IV) Ibuprofen Total Addressable Market (TAM)

6. Intravenous (IV) Ibuprofen Market Segmentation

• 6.1. Global Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conventional Intravenous (IV) Ibuprofen
• High-Concentration Intravenous (IV) Ibuprofen
• 6.2. Global Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 100 Milligrams (mg)
• 200 Milligrams (mg)
• 400 Milligrams (mg)
• 800 Milligrams (mg)
• 6.3. Global Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatrics
• Adults
• 6.4. Global Intravenous (IV) Ibuprofen Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pain
• Fever
• Inflammation
• Other Applications
• 6.5. Global Intravenous (IV) Ibuprofen Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Other End-Users
• 6.6. Global Intravenous (IV) Ibuprofen Market, Sub-Segmentation Of Conventional Intravenous (IV) Ibuprofen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric Intravenous (IV) Ibuprofen
• Adult Intravenous (IV) Ibuprofen
• 6.7. Global Intravenous (IV) Ibuprofen Market, Sub-Segmentation Of High-Concentration Intravenous (IV) Ibuprofen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Vial
• Multi-Dose Vial

7. Intravenous (IV) Ibuprofen Market Regional And Country Analysis

• 7.1. Global Intravenous (IV) Ibuprofen Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Intravenous (IV) Ibuprofen Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Intravenous (IV) Ibuprofen Market

• 8.1. Asia-Pacific Intravenous (IV) Ibuprofen Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Intravenous (IV) Ibuprofen Market

• 9.1. China Intravenous (IV) Ibuprofen Market Overview
• 9.2. China Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Intravenous (IV) Ibuprofen Market

• 10.1. India Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Intravenous (IV) Ibuprofen Market

• 11.1. Japan Intravenous (IV) Ibuprofen Market Overview
• 11.2. Japan Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Intravenous (IV) Ibuprofen Market

• 12.1. Australia Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Intravenous (IV) Ibuprofen Market

• 13.1. Indonesia Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Intravenous (IV) Ibuprofen Market

• 14.1. South Korea Intravenous (IV) Ibuprofen Market Overview
• 14.2. South Korea Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Intravenous (IV) Ibuprofen Market

• 15.1. Western Europe Intravenous (IV) Ibuprofen Market Overview
• 15.2. Western Europe Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Intravenous (IV) Ibuprofen Market

• 16.1. UK Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Intravenous (IV) Ibuprofen Market

• 17.1. Germany Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Intravenous (IV) Ibuprofen Market

• 18.1. France Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Intravenous (IV) Ibuprofen Market

• 19.1. Italy Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Intravenous (IV) Ibuprofen Market

• 20.1. Spain Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Intravenous (IV) Ibuprofen Market

• 21.1. Eastern Europe Intravenous (IV) Ibuprofen Market Overview
• 21.2. Eastern Europe Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Intravenous (IV) Ibuprofen Market

• 22.1. Russia Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Intravenous (IV) Ibuprofen Market

• 23.1. North America Intravenous (IV) Ibuprofen Market Overview
• 23.2. North America Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Intravenous (IV) Ibuprofen Market

• 24.1. USA Intravenous (IV) Ibuprofen Market Overview
• 24.2. USA Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Intravenous (IV) Ibuprofen Market

• 25.1. Canada Intravenous (IV) Ibuprofen Market Overview
• 25.2. Canada Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Intravenous (IV) Ibuprofen Market

• 26.1. South America Intravenous (IV) Ibuprofen Market Overview
• 26.2. South America Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Intravenous (IV) Ibuprofen Market

• 27.1. Brazil Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Intravenous (IV) Ibuprofen Market

• 28.1. Middle East Intravenous (IV) Ibuprofen Market Overview
• 28.2. Middle East Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Intravenous (IV) Ibuprofen Market

• 29.1. Africa Intravenous (IV) Ibuprofen Market Overview
• 29.2. Africa Intravenous (IV) Ibuprofen Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Intravenous (IV) Ibuprofen Market, Segmentation By Strength, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Intravenous (IV) Ibuprofen Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Intravenous (IV) Ibuprofen Market Competitive Landscape And Company Profiles

• 30.1. Intravenous (IV) Ibuprofen Market Competitive Landscape
• 30.2. Intravenous (IV) Ibuprofen Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Fresenius SE & Co. KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Intravenous (IV) Ibuprofen Market Other Major And Innovative Companies

• 31.1. Baxter International
• 31.2. Mylan N.V.
• 31.3. Sandoz Group AG
• 31.4. Grifols S.A.
• 31.5. Dr. Reddy's Laboratories
• 31.6. Hikma Pharmaceuticals plc
• 31.7. CSL Limited
• 31.8. Eurolife Healthcare Pvt. Ltd.
• 31.9. B. Braun Holding GmbH & Co. KG
• 31.10. AFT Pharmaceuticals Ltd
• 31.11. Cumberland Pharmaceuticals Inc.
• 31.12. Delex Pharma International Inc.
• 31.13. Recordati Rare Diseases Inc.
• 31.14. Xgen Pharmaceuticals Djb Inc.
• 31.15. Wellona Pharma

32. Global Intravenous (IV) Ibuprofen Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Intravenous (IV) Ibuprofen Market

34. Recent Developments In The Intravenous (IV) Ibuprofen Market

35. Intravenous (IV) Ibuprofen Market High Potential Countries, Segments and Strategies

• 35.1 Intravenous (IV) Ibuprofen Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Intravenous (IV) Ibuprofen Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Intravenous (IV) Ibuprofen Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34881_Intravenous_IV_Ibuprofen_GMR_2025